USA - NASDAQ:FULC - US3596161097 - Common Stock
Overall FULC gets a fundamental rating of 4 out of 10. We evaluated FULC against 192 industry peers in the Pharmaceuticals industry. While FULC has a great health rating, there are worries on its profitability. FULC has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -4.54% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 20.22 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.42 | ||
| Quick Ratio | 24.42 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.36
-0.64 (-6.4%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.36 | ||
| P/tB | 2.36 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -4.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 21.95% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 24.42 | ||
| Quick Ratio | 24.42 | ||
| Altman-Z | 20.22 |
ChartMill assigns a fundamental rating of 4 / 10 to FULC.
ChartMill assigns a valuation rating of 0 / 10 to FULCRUM THERAPEUTICS INC (FULC). This can be considered as Overvalued.
FULCRUM THERAPEUTICS INC (FULC) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -430.28% in the next year.